Bharat Biotech's COVID-19 shot has 78% efficacy in clinical trials, according to new study
Bharat Biotech's COVID-19 shot has 78% efficacy in clinical trials, according to new study
Bharat Biotech Ltd.'s COVID-19 vaccine has an overall efficacy rate of 77.8% when it comes to preventing symptomatic disease, according to a new study published Thursday in The Lancet. The findings are from a Phase 3 clinical trial conducted in India that had more than 25,000 adult participants; they are in line with the company's previous statements about the vaccine's efficacy rate. The research also found that Covaxin has an efficacy rate of 93.4% at preventing severe disease. The privately held company, which jointly developed the vaccine with the Indian Council of Medical Research, has said Covaxin has been administered to more than 100 million adults worldwide. It is not authorized in the U.S. Ocugen Inc. (OCGN), which has commercialization rights to the vaccine in the U.S., said last week that it has asked the Food and Drug Administration to authorize Covaxin in children between the ages of 2 and 18 years old.
根據週四發表在“柳葉刀”上的一項新研究，巴拉特生物技術有限公司(Bharat Biotech Ltd.)的新冠肺炎疫苗在預防症狀性疾病方面的總有效率為77.8%。這一發現來自於在印度進行的一項3期臨牀試驗，該試驗有超過2.5萬名成年人蔘與；這與該公司之前關於疫苗有效率的聲明是一致的。研究還發現，Covaxin在預防嚴重疾病方面的有效率為93.4%。這傢俬人持股公司與印度醫學研究理事會(Indian Council Of Medical Research)聯合開發了這種疫苗，該公司表示，Covaxin已經在全球超過1億成年人身上接種。在美國擁有疫苗商業化權利的美國Ocugen Inc.(OCGN)上週表示，它已要求美國食品和藥物管理局(Food And Drug Administration)授權Covaxin在2歲至18歲的兒童中使用。Ocugen Inc.(OCGN)在美國擁有該疫苗的商業化權利，該公司未獲授權。
-Jaimy Lee
--傑米·李(Jaimy Lee)